IL6 and prostate carcinoma: Multiple pathways have been shown to induce NED in prostate cancer cells in vitro, including androgen deprivation [56, 57], interleukin-6 (IL-6) treatment [58], Wnt pathway activation [8], EGF signaling pathways [59], activation of the cyclic adenosine 3′, 5′-monophosphate (cAMP) signaling pathway [60–62], or ionizing radiation [63, 64].